Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Companyâs wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Companyâs wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļMDCXW
āļāļ·āđāļāļāļĢāļīāļĐāļąāļMedicus Pharma Ltd
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 11, 2023
āļāļĩāļāļĩāđāļDr. Raza Bokhari, M.D.
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒCompany Warrant
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļ- -
āļāļĩāđāļāļĒāļđāđ100 King Street West
āđāļĄāļ·āļāļTORONTO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ Capital Market Consolidated
āļāļĢāļ°āđāļāļĻCanada
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđM5X 1A4
āđāļāļĢāļĻāļąāļāļāđ17323003046
āđāļ§āđāļāđāļāļāđhttps://medicuspharma.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļMDCXW
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 11, 2023
āļāļĩāļāļĩāđāļDr. Raza Bokhari, M.D.
Mr. Barry Fishman, CPA
Independent Director
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Dr. Larry R. Kaiser
Independent Director
Dr. Edward J. Brennan, Jr., M.D.
Dr. Edward J. Brennan, Jr., M.D.
Chief Scientific Officer, Head of Research and Development Program
Chief Scientific Officer, Head of Research and Development Program
Dr. Sara R. May, Ph.D.
Director
Mr. Frank W. Lavelle
Independent Director
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Mr. Robert J. Ciaruffoli, CPA
Mr. Robert J. Ciaruffoli, CPA
Lead Independent Director
Lead Independent Director
Mr. Andrew A. Smith
Chief Operating Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Barry Fishman, CPA
Independent Director
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Dr. Larry R. Kaiser
Independent Director
Dr. Edward J. Brennan, Jr., M.D.
Dr. Edward J. Brennan, Jr., M.D.
Chief Scientific Officer, Head of Research and Development Program
Chief Scientific Officer, Head of Research and Development Program
Dr. Sara R. May, Ph.D.
Director
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ